differentiated thyroid cancer

Accelerating Radioiodine Therapy in Differentiated Thyroid Cancer: A Novel 24-Hour Diagnostic 131I Scan Protocol Post-rhTSH Administration

By MedXY 08/25/2026

A novel protocol performing diagnostic 131I scans within 24 hours after the second rhTSH injection reliably guides radioiodine therapy in differentiated thyroid cancer, enabling same-cycle pre-treatment evaluation and treatment without schedule alteration.

Diabetes & Endocrinology news Oncology

Long-Term Fatigue in Differentiated Thyroid Cancer Survivors: Early Predictors and the Non-Impact of Thyrotropin Suppression

By MedXY 08/21/2026

A nationwide prospective study identifies early fatigue and poor mental health as key predictors of long-term fatigue in differentiated thyroid cancer patients, while thyrotropin suppression shows no association with fatigue.

news Oncology Pediatrics

Long-Term Risk of Second Primary Malignancies in Pediatric and Young Adult Differentiated Thyroid Cancer Survivors: A Four-Decade Real-World Study

By MedXY 08/17/2026

Pediatric and young adult survivors of differentiated thyroid cancer face a significant long-term risk of second primary malignancies, especially with radioactive iodine treatment, highlighting the need for extended surveillance and tailored therapy.

Diabetes & Endocrinology Family Medicine & Nutrition news

Can Long-Term Thyroid Cancer Follow-Up Safely Move to Primary Care? Prospective Data Support De-Escalation After Excellent Response

By MedXY 05/26/2026

A prospective cohort study suggests that differentiated thyroid cancer patients with sustained excellent response after at least 5 years of specialist follow-up can be safely transitioned to primary care with very low recurrence risk.

news Oncology Pathology & Lab Medicine/Bệnh học

TSH Stimulation Methods Show Comparable Outcomes in Radioiodine-Avid Metastatic Differentiated Thyroid Cancer

By MedXY 05/16/2026

In radioiodine-avid metastatic differentiated thyroid cancer, rhTSH and mixed rhTSH/thyroid hormone withdrawal preparation produced comparable adjusted outcomes. Prognosis was driven mainly by metastatic burden and age, supporting individualized treatment selection.

Cardiology Diabetes & Endocrinology news OB/GYN & Women's Health

Prolonged TSH Suppression in Postmenopausal Thyroid Cancer Patients Linked to Worse Cardiovascular and Quality-of-Life Outcomes

By MedXY 04/28/2026

Study finds long-term TSH suppression in postmenopausal women with thyroid cancer correlates with poorer cardiovascular health, reduced quality of life, and increased osteoporosis risk compared to controls.

Clinical Updates Diabetes & Endocrinology news Oncology Specialties

Postoperative Radioiodine Ablation in Low-Risk Differentiated Thyroid Cancer: Insights from the IoN Trial

By MedXY 08/02/2025

The IoN trial demonstrates that postoperative radioiodine ablation can be safely omitted in most patients with low-risk differentiated thyroid cancer after total thyroidectomy, without compromising recurrence-free survival.